NCT05624294View on ClinicalTrials.gov

Study to Evaluate Safety, Tolerability and Pharmacokinetics of CS0159 in Chinese Healthy Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

December 19, 2022

Primary Completion Date

March 28, 2023

Study Completion Date

March 28, 2023

Conditions
Primary Biliary Cholangitis
Interventions
DRUG

CS0159

Tablets administered orally

DRUG

Placebo

Tablets administered orally

Trial Locations (1)

Unknown

Shanghai Xuhui Central Hospital, Shanghai

Sponsors
All Listed Sponsors
lead

Cascade Pharmaceuticals, Inc

OTHER

NCT05624294 - Study to Evaluate Safety, Tolerability and Pharmacokinetics of CS0159 in Chinese Healthy Subjects | Biotech Hunter | Biotech Hunter